Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syndax Pharma
(NQ:
SNDX
)
18.21
-0.60 (-3.19%)
Streaming Delayed Price
Updated: 1:10 PM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Syndax Pharma
< Previous
1
2
3
Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023
July 11, 2023
Via
Benzinga
Earnings Scheduled For May 8, 2023
May 08, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.
Via
Benzinga
Syndax Pharmaceuticals Earnings Preview
May 05, 2023
Via
Benzinga
Expert Ratings for Syndax Pharmaceuticals
March 01, 2023
Via
Benzinga
Syndax Pharmaceuticals's Earnings: A Preview
February 27, 2023
Via
Benzinga
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Analyst Expectations for Syndax Pharmaceuticals's Future
January 31, 2023
Via
Benzinga
Syndax Highlights Durable Remissions For Revumenib In Acute Leukemia Patients
November 03, 2022
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
Via
Benzinga
United Natural Foods, Ollie's Bargain, Smith & Wesson Brands And Some Other Big Stocks Moving Lower On Wednesday
December 07, 2022
U.S. stocks traded mostly lower, with the Nasdaq Composite dropping over 60 points on Wednesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Earnings Preview For Syndax Pharmaceuticals
November 02, 2022
Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
August 12, 2022
The major indexes continued to advance, despite some key warnings.
Via
Investor's Business Daily
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
August 08, 2022
Amphastar came in well above forecasts, while Syndax had fewer than expected losses.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's After-Market Session
July 07, 2022
Gainers
Via
Benzinga
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
June 30, 2022
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Friday's After-Market Session
April 29, 2022
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
Via
Benzinga
Do Penny Stocks Ever Make Money? Here Are 7 Success Stories
April 10, 2022
Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021. Here are six others.
Via
InvestorPlace
Earnings Scheduled For August 8, 2022
August 08, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.
Via
Benzinga
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022
April 11, 2022
Upgrades
Via
Benzinga
Syndax Pharmaceuticals's Return On Capital Employed Overview
March 07, 2022
According to Benzinga Pro, during Q4, Syndax Pharmaceuticals (NASDAQ:SNDX) earned $96.20 million, a 566.1% increase from the preceding quarter. Syndax Pharmaceuticals also posted...
Via
Benzinga
Recap: Syndax Pharmaceuticals Q4 Earnings
March 01, 2022
Syndax Pharmaceuticals (NASDAQ:SNDX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022
February 15, 2022
Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-...
Via
Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 16, 2021
Gainers Calliditas Therapeutics (NASDAQ:CALT) stock rose 41.09% to $26.3 during Thursday's pre-market session. The market value of their outstanding shares is at $688....
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
December 14, 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with...
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.